Dong Kim - 31 Jan 2023 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Financial Officer
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Issuer symbol
URGN
Transactions as of
31 Jan 2023
Net transactions value
$0
Form type
4
Filing time
02 Feb 2023, 12:05:44 UTC
Previous filing
29 Mar 2022
Next filing
08 Sep 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Award $0 +10,000 $0.000000 10,000 31 Jan 2023 Ordinary Shares 10,000 Direct F1, F2
transaction URGN Employee Stock Option (right to buy) Award $0 +38,000 $0.000000 38,000 31 Jan 2023 Ordinary Shares 38,000 $10.39 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026.
F3 1/3 of the shares underlying the stock options will vest on each of January 31, 2024, January 31, 2025 and January 31, 2026.